Alex Zhavoronkov, PhD, is the founder, CEO and CBO of Insilico Medicine, a leading clinical-stage biotechnology company developing next-generation generative artificial intelligence and automation platforms for drug discovery. Since 2014, he has invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for the generation of novel molecular structures with the desired properties and the generation of synthetic biological and patient data. Under his leadership, Insilico raised over $530 million in multiple rounds from expert biotechnology, healthcare, and financial investors, opened R&D centers in 8 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions.